Immix Biopharma (NASDAQ:IMMX) Trading Down 6.7% Following Weak Earnings

Posted by Brenda Bartman on Aug 9th, 2026

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) shares dropped 6.7% during trading on Friday following a dissappointing earnings announcement. The company traded as low as $9.58 and last traded at $9.3870. Approximately 309,111 shares traded hands during trading, a decline of 75% from the average session volume of 1,229,322 shares. The stock had previously closed at $10.06.

The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.01).

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on IMMX shares. HC Wainwright boosted their price objective on shares of Immix Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, May 22nd. Lifesci Capital initiated coverage on Immix Biopharma in a report on Wednesday, June 17th. They issued an “outperform” rating and a $19.00 target price on the stock. Needham & Company LLC assumed coverage on Immix Biopharma in a research report on Wednesday, July 22nd. They set a “buy” rating and a $21.00 target price on the stock. Bank of America began coverage on Immix Biopharma in a report on Thursday, June 18th. They set a “buy” rating and a $27.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Friday, July 17th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $20.71.

Check Out Our Latest Stock Analysis on IMMX

Institutional Trading of Immix Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of IMMX. Vanguard Group Inc. raised its position in shares of Immix Biopharma by 4.5% during the 3rd quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock valued at $1,526,000 after purchasing an additional 31,625 shares during the period. Tocqueville Asset Management L.P. boosted its holdings in Immix Biopharma by 37.4% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock worth $84,000 after buying an additional 10,950 shares during the period. Imprint Wealth LLC bought a new position in Immix Biopharma in the 3rd quarter worth $141,000. Citadel Advisors LLC purchased a new stake in Immix Biopharma in the 3rd quarter worth $188,000. Finally, Susquehanna International Group LLP increased its stake in Immix Biopharma by 78.8% in the 3rd quarter. Susquehanna International Group LLP now owns 90,858 shares of the company’s stock worth $190,000 after buying an additional 40,032 shares in the last quarter. 11.26% of the stock is owned by hedge funds and other institutional investors.

Immix Biopharma Stock Down 3.4%

The stock has a fifty day simple moving average of $9.38 and a 200 day simple moving average of $8.82. The firm has a market capitalization of $528.87 million, a P/E ratio of -11.05 and a beta of 0.11.

Immix Biopharma Company Profile

(Get Free Report)

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.